Cytosorbents Corporation
Traded as | NASDAQ: CTSO |
---|---|
Industry | Critical care |
Headquarters | Monmouth Junction, New Jersey, USA |
Products | CytoSorb |
Number of employees | 52 |
Cytosorbents Corporation is a publicly traded company (NasdaqCM: CTSO) located in Monmouth Junction, New Jersey.[1][2][3] Cytosorbents has created a blood purification technology based on biocompatible, porous polymer beads that act like sponges in an attempt to remove harmful substances from the blood.[4][5]
CytoSorb, the company's first product to market, received its CE mark approval in 2011.[6][7]
CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency (DARPA) for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins.[8] The US Army awarded the Company a $1.15 million small-business innovation research contract to evaluate the technology in burn and trauma.[9]
References
- ↑ "CTSO: Summary for CYTOSORBENTS COR- Yahoo! Finance". YAHOO Finance. Retrieved 9 April 2014.
- ↑ "CTSO stock quote – Cytosorbents Corporation stock price – NASDAQ.com". NASDAQ. Retrieved 9 April 2014.
- ↑ "CTSO SEC Filings". YAHOO. Retrieved 9 April 2014.
- ↑ Baum, Stephanie. "Blood purification device for ICU patients seeks to control cytokine storm". Med City News. Retrieved 2013-05-24.
- ↑ "Septic shock secondary to β-hemolytic streptococcus-induced necrotizing fasciitis treated with a novel cytokine adsorption therapy". The International Journal of Artificial Organs. Retrieved 6 May 2014.
- ↑ Crutcher, Patrick. "Closer Look: CytoSorbents' Surprise CE Mark Approval". BioMed Reports. Retrieved 4/1/11. Check date values in:
|access-date=
(help) - ↑ "With EU Regulatory Approval Gained CytoSorbents Corporation (OTCBB: CTSO) One Step Closer to Goal of FDA Regulatory Approval". OTC Equity. Retrieved 9 April 2014.
- ↑ "DARPA Dialysis-Like-Therapeutic Program Awards $3.8M to CytoSorbents". Global BioDefense. Retrieved 9 April 2014.
- ↑ "CTSO Awarded Ph II U.S. Army Grant". Zacks. Retrieved 9 April 2014.